header logo image


Page 24«..1020..23242526..3040..»

Archive for the ‘Regenerative Medicine’ Category

COLUMN Worried about your immune system? Try these 5 natural remedies – Body aches fever chills and nasal congestion common symptoms of the flu can…

Thursday, April 16th, 2020

San Diego Community News Group

Complications arising from these illnesses can become serious, says Dr. Suhyun An (drsuhyunan.com), an expert on regenerative medicine and co-author of Demystifying Stem Cells: A Real-Life Approach To Regenerative Medicine.

An says there are ways to prevent the symptoms from reaching that serious point. To feel better and get back on your feet, she recommends numerous natural cold and flu remedies to alleviate your symptoms:

Vitamin C. Some studies indicate that vitamin C can shorten the lifespan of a cold and boost your immune system. The best way to get it is through your diet; the fresher the food, the better, An says. Oranges, limes, lemons, grapefruits, leafy greens, and bell peppers are all good sources of vitamin C. Be careful with supplements because they can lead to upset stomach and kidney stones.

Honey. Honey has natural antiviral and antimicrobial properties. Drinking honey in tea with lemon can ease sore throat pain, An says. Research suggests that honey is an effective cough suppressant, too. Honey often contains Clostridium bacteria, so never give honey to a child younger than 1-year-old because infants immune systems arent able to fight them off.

Chicken soup. This popular cold and flu remedy helps because hot liquids reduce mucus buildup and keep you hydrated. Chicken soup, in particular, has anti-inflammatory properties, which help reduce a colds unpleasant side effects, An says. Keep some in the freezer or even canned for flu season. Its quick to prepare that way and soothing to eat.

Aromas. When you have congestion from the flu, applying camphor or menthol salve around your nose can help break up mucus, An says. Aromatherapy oils, such as peppermint and eucalyptus, can have a similar effect. Also, vapor rub can reduce cold symptoms, especially in children older than 2 years. It helps open air passages to combat congestion, reduce coughing, and improve sleep. Its a good alternative to over-the-counter cold medicines in young children because of unwanted side effects.

Probiotics. These are friendly bacteria and yeast found in the body, some foods, and supplements. They can help keep your gut and immune system healthy, and they may reduce your chance of getting sick with an upper respiratory infection, An says. For a delicious and nutritious source of helpful bacteria, include probiotic yogurt in your diet.

Colds and the flu are threats to us every year, but they dont have to get us down for long, An says. Natural home remedies can reduce symptoms so you can be more comfortable and get the rest you need to get better faster.

Dr. Suhyun An is the clinic director at Campbell Medical Group in Houston and an expert on regenerative medicine.

See the original post:
COLUMN Worried about your immune system? Try these 5 natural remedies - Body aches fever chills and nasal congestion common symptoms of the flu can...

Read More...

Global Cartilage Repair and Regeneration Market, by Treatment Modalities, Procedure Type and Application to 2022 – Yahoo Finance

Wednesday, April 1st, 2020

Dublin, April 01, 2020 (GLOBE NEWSWIRE) -- The "Global Cartilage Repair and Regeneration Market, by Treatment Modalities (Cell-Based Approach, Non-Cell-Based Approach), by Procedure Type, by Application, Outlook 2022" report has been added to ResearchAndMarkets.com's offering.

Due to changing lifestyle, a number of disorders like obesity and degenerative joint diseases are affecting the masses across the globe. These factors directly or indirectly develop cartilage injuries; and lead to a decline in the productivity of the working population, which ultimately causes some degree of disability. Therefore, increasing epidemiology of such diseases requires effective treatment options, generating significant demand for regenerative medicine used to restore damaged cartilage.

According to this new release, Global Cartilage Repair and Regeneration Market, by Treatment Modalities (Cell-Based Approach, Non-Cell-Based Approach), by Procedure Type, by Application Outlook 2022 , the industry is expanding at a fast pace. As per this report, the Cartilage Repair and Regeneration market are anticipated to witness high double-digit growth during the forecasted period (2016-2022). This report provides a detailed analysis of the current and future market scenario of the global Cartilage Repair and Regeneration market. The report provides insight into the major factors affecting growth, latest innovations, market segmentation, and competitive landscape.

The report segments the market on the basis of the treatment modalities, procedure type, applications, and geography, with the future forecasts on all prominent segments of the industry till 2022.

Based on treatment modality, the cell-based approaches segment accounts for the largest market share in the overall cartilage repair and regeneration market, due to long-term results of these therapies.

In terms of procedure type, microfracture and ACI are the most common procedure observed amongst all the types of the cartilage repair procedure. Furthermore, in terms of application, the hyaline cartilage repair and regeneration market accounts for the largest share in 2016. It is also expected to be the fastest-growing application segment in the cartilage repair and regeneration market. The large share and high growth of this segment can be attributed to the high prevalence of cartilage damage in hyaline cartilage.

Based on geography, the report divides the market into North America, Europe, and Asia-Pacific. In 2016, North America holds the major share in the market. However, the Asia-Pacific region is slated to witness the highest growth in the forecasted period. The growth of the Asia-Pacific market is driven by improving healthcare facilities, raising awareness, increasing prevalence of rheumatoid and osteoarthritis, and increasing government initiatives in this region.

The report finally covers the competitive analysis of the key market players, in terms of their market share and their product offerings. The key vendors dominating the market space are Stryker Corp., Zimmer Biomet Holdings Inc., Smith & Nephew Plc, DePuy Synthes, Inc., etc. The competitive analysis is done at each player level, including their recent developments. To provide a thorough understanding of each player's business model, the player's current and historical financials have been analyzed. Thus, the report provides a comprehensive analysis of cartilage repair & regeneration technology, which will enable investors to design suitable business strategies to target this market.

Key Topics Covered:

1. Analyst View

2. Research Methodology

3. Cartilage Repair-Overview

4. Market Dynamics4.1 Drivers4.1.1 Growing Incidences of Chondrodystrophies leading to Cartilage Injuries4.1.2 Rising Incidences of Orthopedic Diseases4.1.3 Surge in Sports Injuries4.1.4 Growing Geriatric Popuation4.1.5 Rising Prevalence of Obesity4.1.6 Technological Advancements4.2 Challenges4.2.1 Limited Health Insurance Coverage in Developing Countries4.2.2 High Cost of Knee Cartilage Repair Surgeries4.2.3 Complexity of Cartilage Repair Surgeries4.3 Opportunities4.3.1 Significant US Market Opportunity Due to Unsatisfactory First Line Therapies4.3.2 Emerging Economies to Offer Sustained Growth Opportunities4.3.3 Increased R&D Spending for Advancements in Knee Cartilage Repair4.3.4 Use of Bioactive Growth Factors4.3.5 3D Printing

5. Global Cartilage Repair and Regeneration Market Outlook 2022

6. Cartilage Repair and Regeneration Market, By Treatment Modalities6.1 Cell-Based Approach6.2 Non-Cell-Based Approach

7. Global Cartilage Repair and Regeneration Market, By Procedure Type7.1 Autologous Chondrocyte Transplantation7.2 Cell-Based Cartilage Resurfacing7.3 Microfracture7.4 Osteochondral Allograft7.5 Others

8. Global Cartilage Repair and Regeneration Market, By Application8.1 Hyaline Cartilage Repair and Regeneration8.2 Elastic Cartilage Repair and Regeneration8.3 Fibrous Cartilage Repair and Regeneration

9. Global Cartilage Repair and Regeneration Market, By Geography9.1 North America9.2 Europe9.3 Asia-Pacific

10. Regulatory Landscape

11. Trends & Developments11.1 Cost-Effectiveness Promoting Interest in One-Step Surgery11.2 Bioactive Signals that Enhance Cartilage Repair11.3 Gene Therapy for Cartilage Repair11.4 Mesenchymal Stem Cells

12. Competitive Landscape12.1 Market Share of Key Players12.2 Comparative Analysis of Products

13. Key Players Analysis13.1 Stryker Corporation13.2 B. Braun Melsungen AG13.3 Zimmer Biomet Holdings, Inc.13.4 Smith & Nephew plc13.5 DePuy Synthes, Inc. (A Subsidiary of Johnson & Johnson)13.6 Arthrex, Inc.13.7 Osiris Therapeutics, Inc.13.8 Vericel Corporation13.9 RTI Surgical, Inc.13.10 CONMED Corporation13.11 Anika Therapeutics, Inc.

14. The Future of Cartilage Repair

Story continues

For more information about this report visit https://www.researchandmarkets.com/r/sd7qmv

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

Read the rest here:
Global Cartilage Repair and Regeneration Market, by Treatment Modalities, Procedure Type and Application to 2022 - Yahoo Finance

Read More...

Avectas partners with Vycellix to speed cell therapy production – BioPharma-Reporter.com

Wednesday, April 1st, 2020

Avectas will provide access to its Solupure platform, which Vycellix will use to deliver its product candidate, VY-M, to T cells and NK cells.

According to Vycellixs president, Douglas Calder, the use of Solupure will allow for the accelerated expansion time of T cells and NK cells by decreasing the non-dividing lag times the overall aim being to reduce the vein-to-vein delivery time to patients.

In addition, the companies hope to reduce the cost of manufacture and to develop proprietary approaches for cell-based immunotherapeutic products.

Both companies are partners within NextGenNK, a center based on the development of NK cell-based cancer immunotherapies in Stockholm, Sweden.

The collaborative studies that will occur between the two partners will be divided between the Karolinska Institutet and Avectas Dublin, Ireland facility.

Vycellix willl use this platform to aid in the development of its pipeline of therapies, which includes VY-101 a retargeted optimized NK cell therapy. The company hopes to be able to submit an investigational new drug filing in 2021 for the treatment candidate.

Avectas recently signed an agreement to also utilize the platform alongside the Centre for Commercialization of Regenerative Medicine to speed up the cell engineering process.

The companys Solupure platform uses membrane disruption to deliver nucleic acids and proteins to cells rather than viral cell engineering.

Read more:
Avectas partners with Vycellix to speed cell therapy production - BioPharma-Reporter.com

Read More...

LETTERS TO THE EDITOR | Opinion – Moscow-Pullman Daily News

Wednesday, April 1st, 2020

I want to add to the praise for the healthcare workers and first responders who are literally our front line in fighting this war we are in against a virus called COVID-19. As a retired medical technologist, I know that drive to do all we can to save the lives of others and not stopping for breaks or meals or even sleep until the work is done. I, thank God, was never in a battle that went on for days and weeks and now months, nor one where my life was at risk everyday when I went to work. Each and every one of you is a hero beyond compare.

In this same war, I am thinking we have not expressed enough praise for another group of frontline workers: those who are working in our grocery stores, hardware stores, drug stores and restaurants to keep us supplied with the essentials we need through this crisis. You are also at higher risk of being exposed than those of us who get to stay home. In positions that have been taken for granted by so many of us in our busy lives, we can now see you for the hugely important role you have always played in keeping society moving smoothly. Thank you.

Support for the most vulnerable

I am writing you to urge the support of legislation that addresses the needs of the most vulnerable:

1) $60 billion for the charitable sector and the construction of a mechanism for a rapid infusion of cash to those organizations serving immediate needs in communities while facing lost and declining revenue due to the pandemic.

2) Create a universal charitable deduction and allow post-March 1, 2020, donations to be claimed on 2019 taxes and future tax returns.

3) Clarify that charitable nonprofits of all sizes are able to participate in the emergency small business loan program by using the tax-law definition of charitable organizations (Sec. 501(c)(3) public charities).

4) Remove the cap on the number of employees and the language excluding nonprofits from receiving Medicaid reimbursements.

5) Increase funding for the Emergency Food and Shelter Program from the existing FY 2020 $125 million to $250 million to help people experiencing dire poverty.

6) Temporarily increase the maximum SNAP benefit.

7) Increase funding to prevent further homelessness. Provide an additional $15 billion for McKinney-Vento Emergency Solutions Grants and $5 billion for short-term rental assistance, like the Disaster Housing Assistance Program.

Thank you for acting in the welfare of the most vulnerable. Our society can only be as strong as our weakest links.

Making a false supposition

In Kenneth Gordons March 26 letter, (Facts vs. Hysteria), he maintained a false supposition: that COVID-19 is a form of flu. COVID-19 is not a form of flu, it is more akin to another coronavirus, the very deadly SARS (Severe Acute Respiratory Syndrome).

COVID-19 is a novel coronavirus, which is an infectious respiratory illness as is influenza; but this is a brand new virus. That means unlike the flu, which has a vaccine and several pharmaceutical therapies (including oseltamivir phosphate or Tamiflu), there are no vaccines or medicines available to treat the illness yet. Clinical trials for effective treatments and vaccines takes time. Another major concern is because COVID-19 is so new, scientists and medical researchers do not yet know if there are any long-term medical implications with this new virus or how frequently it mutates.

What the medical community does know is this new virus kills at a higher rate than influenza. Currently, the Journal of the American Medical Association estimates the virus is killing at a rate of 2.7 percent compared to a death rate of 1 percent for influenza, although the death rate in Italy is 7.2 percent. The World Health Organization is currently saying little slows this bug down, except for being well informed: Social distancing, sneezing/coughing into elbows and people being vigilant in not touching their face plus hand washing, and paying attention to any symptoms.

So, rather than worry about going back to work, instead consider your fellow humans while you may only show few or no symptoms, that germ you pass on may kill another person. Is going back to work fast really worth that risk?

Knowing it is all for the best

I am always thinking of ways to keep in touch with old friends and family from afar, so I am using this letter to the editor to more widely let known I am fine and am not affected yet by COVID 19.

Because of my interest in history, I have been thinking about other pandemics such as typhoid fever and polio and am encouraged by the fact that these diseases are no longer a threat. My grandfather, I believe, contracted typhoid fever from drinking contaminated water in the Wisconsin Dells.

And I remember how relieved I was during the polio epidemic to finally be able to take polio vaccine. We have come a long way with penicillin other miracle drugs, and I want to put in a plug for the advances in regenerative medicine now on the horizon, specifically stem cell therapy that I underwent this past year. One of the advantages of that is that it only took a half day and I could avoid a prolonged hospital stay. With the fear of contamination and spread of viruses, that was significant for me. I miss seeing you all but know it is for the best.

Drinking poison wastheir own mistake

Propylene glycol is used in many processed foods. Ethylene glycol is the main ingredient in antifreeze. They have similar names, but you wouldnt want to drink antifreeze. That would be stupid. Im sure that Charlie Powell (Tooth & Nail, Daily News), who I believe has a personal acquaintance with veterinarians at WSU, has seen what happens to dogs that dip their tongues in antifreeze.

Recently, we learned of an unfortunate couple of people who tried to self-medicate by drinking poison. The poison has a name similar to a common drug that could be an effective treatment for COVID-19. That is very sad, but obviously it was less than wise.

The drug in question has been safely used for decades to treat a variety of ailments, and doctors around the world have seen promising results against the new coronavirus. Mr. Powell, in his March 28 column, notes that there is an elected official who has mentioned this hopeful development, and then clearly suggests that the elected official is responsible for the actions of those unfortunately mistaken people. Negative, Mr. Powell!

People need to be aware of what they are doing, and if they purposely drink poison, its their own mistake. Theirs alone. Sad, but true.

See the original post here:
LETTERS TO THE EDITOR | Opinion - Moscow-Pullman Daily News

Read More...

Allergan Earns ENERGY STAR Partner of the Year – Sustained Excellence Award for the Seventh Consecutive Year – Yahoo Finance

Wednesday, April 1st, 2020

DUBLIN, March 31, 2020 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced it has received the ENERGY STAR Partner of the Year Sustained Excellence Award for 2020, marking the seventh consecutive year it has earned ENERGY STAR'shighest honor. The U.S. Environmental Protection Agency award recognizes Allergan for its continued leadership in energy management and efficiency.

"Allergan is proud of its longstanding commitment to increasing our energy efficiency and reducing our impact on the environment. Four years ago, we set an aggressive goal to reduce our total energy usage by 20 percent between 2015 and 2020 and today we are well on our way to achieving that goal. We congratulate our global colleagues for their tremendous efforts to support environmental responsibility, which continue to be recognized year after year," saidWayne Swanton, Executive Vice President, Global Operations atAllergan.

Prior to earning the ENERGY STAR Sustained Excellence distinction for the last seven years, Allergan was recognized as an ENERGY STAR Partner of the Year for two consecutive years. Additionally, Allergan's manufacturing facility in Waco, Texas was recently named an ENERGY STAR Certified Manufacturing Plant for superior energy performance, a distinction earned only by plants in the top 25 percent of energy performance in the United States. Allergan also achieved ENERGY STAR certification for a building located at its Irvine, California campus.Allerganhas been an ENERGY STARpartner since 1996.

For a complete list of 2020 winners and more information about ENERGY STAR's awards program, visit energystar.gov/awardwinners.

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan markets a portfolio of leading brands and best-in-class products primarily focused on four key therapeutic areas including medical aesthetics, eye care, central nervous system and gastroenterology. As part of its approach to delivering innovation for better patient care, Allergan has built one of the broadest pharmaceutical and device research and development pipelines in the industry.

With colleagues and commercial operations located in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan's website atwww.Allergan.com.

About ENERGY STAR

ENERGY STARis the government-backed symbol for energy efficiency, providing simple, credible, and unbiased information that consumers and businesses rely on to make well-informed decisions. Thousands of industrial, commercial, utility, state, and local organizationsincluding more than 40 percent of the Fortune 500 companiesrely on their partnership with EPA to deliver cost-saving energy efficiency solutions. Since 1992, ENERGY STAR and its thousands of partners helped American families and businesses save more than 4 trillion kilowatt-hours of electricity and achieve over 3.5 billion metric tons of greenhouse gas reductions. In 2018 alone, ENERGY STAR and its partners helped Americans avoid nearly $35 billion in energy costs. More background information about ENERGY STAR can be found at: energystar.gov/about and energystar.gov/numbers.

Story continues

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS, on our financial results; risks associated with divestitures, acquisitions, mergers and joint ventures; risks related to impairments; uncertainty associated with financial projections, projected cost reductions, projected debt reduction, projected synergies, restructurings, increased costs, and adverse tax consequences;difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2019. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

CONTACTS:

Allergan: Investors:Manisha Narasimhan, PhD(862) 261-7488

Media:Lisa Brown(862) 261-7320

View original content to download multimedia:http://www.prnewswire.com/news-releases/allergan-earns-energy-star-partner-of-the-year--sustained-excellence-award-for-the-seventh-consecutive-year-301032547.html

SOURCE Allergan plc

Continue reading here:
Allergan Earns ENERGY STAR Partner of the Year - Sustained Excellence Award for the Seventh Consecutive Year - Yahoo Finance

Read More...

Here are the departments accepting S/NC in spring 2020 – The Stanford Daily

Wednesday, April 1st, 2020

On Thursday, the Faculty Senate voted 36-15 to mandate that all spring quarter courses be graded on a satisfactory/no-credit (S/NC) basis. Courses in the Stanford Graduate School of Business, Stanford Law School and Stanford School of Medicines M.D. program were exempt from this decision, but those schools may opt in.

The Senate also approved a measure that strongly urges departments and programs to exclude units of credit earned for a CR or S grade during spring quarter 2019-20 from program unit maximums and/or alter program requirements as appropriate.

The Daily has reached out to all of Stanfords departments, schools and programs that offer undergraduate and/or graduate degrees to compile a list of those accepting courses taken on a S/NC basis this spring for degree requirements. Ways of Thinking/Ways of Doing, Thinking Matters and Program in Writing and Rhetoric courses taken S/NC in the spring will also count toward undergraduate graduation requirements.

No departments, schools or programs have yet said that they will not be accepting courses taken S/NC this spring. The following list will be updated as The Daily receives additional responses.

Graduate School of EducationEducation (Minor)

School of Earth, Energy & Environmental Sciences (All degrees)

School of EngineeringAeronautics and Astronautics (Major, Minor)Architectural Design (Major)Atmosphere and Energy (Major)Bioengineering (All degrees)Biomechanical Engineering (Major)Biomedical Computation (Major)Chemical Engineering (Major, Minor)Civil Engineering (Major, Minor)Computer Science (Major, Minor, M.S.)Electrical Engineering (Major, Minor)Engineering Physics (Major)Environmental Systems Engineering (Major, Minor)Management Science and Engineering (Major, Minor)Materials Science and Engineering (Major, Minor)Mechanical Engineering (All degrees)Product Design (Major)

School of Humanities & SciencesAmerican Studies (Major, Minor)Applied Physics (All degrees)Archaeology (Major, Minor)Biology (Major, Minor)Center for Comparative Studies in Race & Ethnicity (Major, Minor)Chemistry (Major, Minor)Classics (Major, Minor)Communication (All degrees)Creative Writing (Minor)Data Science (Minor)Division of Literatures, Cultures, and Languages (All degrees)Economics (Major, Minor)English (Major, Minor)Human Biology (Major, Minor)Human Rights (Minor)International Relations (Major, Minor)Linguistics (Major, Minor)Mathematical and Computational Science (Major, Minor)Mathematics (Major, Minor)Music (Major, Minor)Philosophy (Major, Minor)Physics (Major, Minor)Political Science (Major, Minor)Psychology (Major, Minor)Public Policy (Major, Minor)Religious Studies (Major, Minor)Sociology (Major, Minor)Statistics (Minor)Symbolic Systems (Major, Minor)Urban Studies (Major, Minor)

School of MedicineBiochemistry (All degrees)Bioengineering (All degrees)Biomedical Informatics (All degrees)Biophysics (All degrees)Cancer Biology (All degrees)Chemical and Systems Biology (All degrees)Epidemiology & Clinical Research (M.S., Ph.D.)Genetics (All degrees)Health Policy (M.S., Ph.D.)Immunology (All degrees)Microbiology and Immunology (All degrees)Neurosciences (All degrees)Stem Cell Biology and Regenerative Medicine (All degrees)

Contact Camryn Pak at cpak23 at stanford.edu.

See the original post here:
Here are the departments accepting S/NC in spring 2020 - The Stanford Daily

Read More...

Coronavirus: BU Wednesday Roundup | BU Today – BU Today

Wednesday, April 1st, 2020

If you have a question or comment related to BU and its response to the COVID-19 crisis, on the subject of the move-out, remote learning, retrieving personal belongings, or anything else, please visit Boston Universitys special COVID-19 website. Questions are being answered there by specific departments in a timely fashion. Thank you. Doug Most, executive editor, BU Today

Even the dogs wont come downstairs.

Number killed in the 9/11 attacks:

2,977

BU-based Boston Playwrights Theatre (BPT) will present a very different Boston Theater Marathon when the annual event begins today, Wednesday, April 1, and it might be just the distraction that all us shut-ins need.

More than 200 Boston-area theater artists are working on Boston Theater Marathon XXII: Special Zoom Edition, which features 10-minute plays written by New England playwrights and presented by New England theater companies. There will be one broadcast every day at noon for more than a month on Zoom, the videoconferencing tool that just about everyone is using to stay in touch these days. Find a complete schedule, with Zoom links, here.

The Elliot Norton Awardwinning marathon, a yearly community-based charity event benefiting the Theatre Community Benevolent Fund, was scheduled for April 19, but was canceled as the coronavirus pandemic escalated earlier this month. Audiences who dial in to the event will be encouraged to donate to participating theater companies and/or to the Theatre Community Benevolent Fund.

We wont let this necessary distancing stop these gifted playwrights and these wonderful companies from coming together to celebrate new work, says BPT and Marathon artistic director Kate Snodgrass (GRS90), a College of Arts & Sciences professor of the practice of playwriting. Theater will continuewhether its on the stage or in our hearts (or rather, in this case, on Zoom). Whether its for 10 minutes or for 10 hours, art lives.

This years Theater Marathon was intended to be a homecoming of sortsthe first time the event had been held at Boston Playwrights Theatre since 2004. (It was at the Huntington Theatre Companys Virginia Wimberly Theatre at the Boston Center for the Arts from 2005 to 2019.) Instead of honoring our past, times dictate that we try something new, says K. Alexa Mavromatis (GRS11), BPT marketing director.

Todays first installment is Three Ladybugs, by Vicki Meagher, sponsored by Boston Playwrights Theatreand featuring an all-BU cast. Its directed by Darren Evans (CAS95), stars Melinda Lopez (GRS00), a CAS adjunct assistant professor of playwriting, as Atheist Ladybug, and veteran Boston stage actors Paula Plum (CFA75) as Agnostic Ladybug and Karen McDonald (CFA72) as Believer Ladybug. Snodgrass and Evans have voice-over parts (Woman and Man) and Mavromatis will read stage directions. Playwrights represented this year include Mavromatis and Ronn Noone (GRS01), as well as local stalwarts like Patrick Gabridge and John Kuntz (GRS05).

The Theater Marathon is traditionally presented as a 10-hour, all-day affair featuring 10-minute plays by 50 New England playwrights and produced by 50 New England theater companies. Instead, this year it will be a daily Zoom-based lunch break through May 17. Readings will begin each day at noon and last approximately 15 minutes. Audiences will need to download the free Zoom app to participate, and it is recommended that they call in a few minutes before curtain time. Nearly every playwright and theater company tapped to participate in the onstage version will be part of the Zoom event.

And yes, the Zoom events will be set up so only the performers are seen and heard.

On Thursday, April 2, all BU alumni, students, faculty, and staff across the globe are asked to wear BU gear for the day and post proudly across social channels using #TerriersTogetheralong with messages of positivity and connection for the BU community. The #TerriersTogether web page asks students and alums to:

The page also offers downloadable Zoom backgrounds so at your next meeting you can make it look like youre at the BU Beach or the GSU.

A couple of BU Today stories we want to be sure you didnt miss: 50 Boston collaborators gathered at the Center for Regenerative Medicine (CReM) on Boston Universitys Medical Campus in March to develop their own FDA-approved coronavirus test. A Questrom supply-chain expert says stock up, yes, but dont panic about food supplies. Also: Former Patriots tight end Rob Gronkowski and model Camille Kostek have donated 10,000 medical-grade KN95 masks to both Boston Medical Center and St. Josephs University Medical Center in New Jersey, in an effort to assist with the high demand for personal protective equipment (PPE) during the pandemic. And finally, if you have followed the conventional wisdom as it evolves toward everybody wear a mask when you go outside, heres how to make your own.

The Massachusetts governor announced Tuesday that he is extending the order closing nonessential businesses and that the state Department of Public Health will keep its stay-at-home advisory in place, both until May 4, matching planned school closures. Gatherings larger than 10 people are also banned. The White House on Sunday extended guidelines for Americans to maintain social distancing through April 30.

An updated list of essential businesses is being distributed. Among the changes: hotels, motels, and short-term rentals like AirBnBs can no longer be booked for leisure purposes. They may be used only for efforts related to fighting COVID-19, like frontline health workers, or for Massachusetts residents who have been otherwise displaced from their residences. People should really be using common sense and not going on vacation right now, Baker said.

The FBI has received multiple reports of conferences being disrupted by pornographic and/or hate images and threatening language, the Boston Globe reports. Apparently, now that were all using Zoom to study and stay connected in an age of social distancing, it has become fertile ground for trolls and hate-mongers. The feds recommend that you use passwords and other Zoom features to prevent disrupters from getting into your work meetings and virtual cocktail parties.

The White House released the epidemiological models of the spread of coronavirus in the United States that painted such a grim picture that President Trump gave up his plan to reopen the country on Easter. Trump warned Americans of a very, very painful two weeks ahead. The models showed the virus is likely to kill 100,000 to as many as 240,000Americans this year. Trump now says social distancing and business closures will continue through April.

A nationwide trial is underway to see if the drug hydroxychloroquine can prevent disease in people exposed to the novel coronavirus. A second trial will test to see if the drug can prevent severe disease in people who are already showing COVID-19 symptoms. Both are run by a University of Minnesota infectious disease specialist.

United States, 174,467; Massachusetts, 6,620.

FindBU Todays latest coverage of the pandemichere. The Universitys hotline for faculty, staff, students, and visiting scholars to call for referral of their virus-related medical concerns is 617-358-4990.

Read the original post:
Coronavirus: BU Wednesday Roundup | BU Today - BU Today

Read More...

2020 Canada Gairdner Awards Recognize World-renowned Scientists for Transformative Contributions to Research That Impact Human Health – Benzinga

Wednesday, April 1st, 2020

TORONTO, March 31, 2020 /CNW/ - The Gairdner Foundation is pleased to announce the 2020 Canada Gairdner Award laureates, recognizing some of the world's most significant biomedical research and discoveries. During these challenging times, we believe it is important to celebrate scientists and innovators from around the world and commend them for their tireless efforts to conduct research that impacts human health.

2020 Canada Gairdner International AwardThe five 2020 Canada Gairdner International Award laureates are recognized for seminal discoveries or contributions to biomedical science:

Dr. Masatoshi TakeichiSenior Visiting Scientist, RIKEN Center for Biosystems Dynamics Research, Kobe, Japan; Professor Emeritus, Kyoto University, Kyoto, Japan

Dr. Rolf KemlerEmeritus Member and Director, Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany

Awarded "For their discovery, characterization and biology of cadherins and associated proteins in animal cell adhesion and signalling."

Dr. Takeichi

The Work: The animal body is made up of numerous cells. Dr. Takeichi was investigatinghow animal cells stick together to form tissues and organs, and identified a key protein which he named 'cadherin'.Cadherin is present on the surface of a cell and binds to the same cadherin protein on the surface of another cell through like-like interaction, thereby binding the cells together. Without cadherin, cell to cell adhesion becomes weakened and leads to the disorganization of tissues. Dr. Takeichi found that there are multiple kinds of cadherin within the body, each of which are made by different cell types, such as epithelial and neuronal cells. Cells with the same cadherins tend to cluster together, explaining the mechanism of how different cells are sorted out and organized to form functional organs.

Further studies by Dr. Takeichi's group showed that cadherin function is supported by a number of cytoplasmic proteins, includingcatenins, and their cooperation is essential for shaping of tissues. His studies also revealed that the cadherin-dependent adhesion mechanism is involved in synaptic connections between neurons, which are important for brain wiring.

Dr. Kemler

The Work: Dr. Kemler, using an immunological approach, developed antibodies directed against surface antigens of early mouse embryos. These antibodies were shown to prevent compaction of the mouse embryo and interfered with subsequent development. Both Dr. Kemler and Dr. Takeichi went on to clone and sequence the gene encoding E-cadherin and demonstrate that it was governing homophilic cell adhesion.

Dr. Kemler also discovered the other proteins that interact with the cadherins, especially the catenins, to generate the machinery involved in animal cell-to-cell adhesion. This provided the first evidence of their importance in normal development and diseases such as cancer. It has been discovered that cadherins and catenins are correlated to the formation and growth of some cancers and how tumors continue to grow. Beta catenin is linked to cell adhesion through interaction with cadherins but is also a key component of the Wnt signalling pathway that is involved in normal development and cancer. There are approximately 100 types of cadherins, known as the cadherin superfamily.

Dr. Takeichi

The Impact: The discovery of cadherins, which are found in all multicellular animalspecies, has allowed us to interpret how multicellular systems are generated and regulated. Loss of cadherin function has been implicated as the cause of certain cancers, as well as in invasiveness of many cancers. Mutations in special types of cadherin result in neurological disorders, such as epilepsy and hearing loss. The knowledge of cadherin function is expected to contribute to the development of effective treatments against such diseases.

Dr. Kemler

The Impact: Human tumors are often of epithelial origin. Given the role of E-cadherin for the integrity of an epithelial cell layer, the protein can be considered as a suppressor of tumor growth. The research on the cadherin superfamily has had great impact on fields as diverse as developmental biology, cell biology, oncology, immunology and neuroscience. Mutations in cadherins/catenins are frequently found in tumors. Various screens are being used to identify small molecules that might restore cell adhesion as a potential cancer therapy.

Dr. Roel NusseProfessor & Chair, Department of Developmental Biology; Member, Institute for StemCell Biology andRegenerativeMedicine, Stanford University, School of Medicine.Virginia and Daniel K. Ludwig Professor of Cancer Research. Investigator, Howard Hughes Medical Institute

Awarded"For pioneering work on the Wnt signaling pathway and its importance in development, cancer and stem cells"

The Work: Dr. Nusse's research has elucidated the mechanism and role of Wnt signaling, one of the most important signaling systems in development. There is now abundant evidence that Wnt signaling is active in cancer and in control of proliferation versus differentiation of adult stem cells, making the Wnt pathway one of the paradigms for the fundamental connections between normal development and cancer.

Among Dr. Nusse's contributions is the original discovery of the first Wnt gene (together with Harold Varmus) as an oncogene in mouse breast cancer. Afterwards Dr. Nusse identified the Drosophila Wnt homolog as a key developmental gene, Wingless. This led to the general realization of the remarkable links between normal development and cancer, now one of the main themes in cancer research. Using Drosophila genetics, he established the function of beta-catenin as a mediator of Wnt signaling and the Frizzleds as Wnt receptors (with Jeremy Nathans), thereby establishing core elements of what is now called the Wnt pathway. A major later accomplishment of his group was the first successful purification of active Wnt proteins, showing that they are lipid-modified and act as stem cell growth factors.

The Impact: Wnt signaling is implicated in the growth of human embryos and the maintenance of tissues. Consequently, elucidating the Wnt pathway is leading to deeper insights into degenerative diseases and the development of new therapeutics. The widespread role of Wnt signaling in cancer is significant for the treatment of the disease as well. Isolating active Wnt proteins has led to the use of Wnts by researchers world-wide as stem cell growth factors and the expansion of stem cells into organ-like structures (organoids).

Dr. Mina J. Bissell Distinguished Senior Scientist, Biological Systems and Engineering Division, Lawrence Berkeley National Laboratory; Faculty; Graduate Groups in Comparative Biochemistry, Endocrinology, Molecular Toxicology and Bioengineering, University of California Berkeley, Berkeley, CA, USA

Awarded "For characterizing "Dynamic Reciprocity" and the significant role that extracellular matrix (ECM) signaling and microenvironment play in gene regulation in normal and malignant cells, revolutionizing the fields of oncology and tissue homeostasis."

The Work: Dr. Mina Bissell's career has been driven by challenging established paradigms in cellular and developmental biology. Through her research, Dr. Bissell showed that tissue architecture plays a dominant role in determining cell and tissue phenotype and proposed the model of 'dynamic reciprocity' (DR) between the extracellular matrix (ECM) and chromatin within the cell nucleus. Dynamic reciprocity refers to the ongoing, bidirectional interaction between cells and their microenvironment. She demonstrated that the ECM could regulate gene expression just as gene expression could regulate ECM, and that these two phenomena could occur concurrently in normal or diseased tissue.

She also developed 3D culture systems to study the interaction of the microenvironment and tissue organization and growth, using the mammary gland as a model.

The Impact:Dr. Bissell's model of dynamic reciprocity has been proven and thoroughly established since its proposal three decades ago and the implications have permeated every area of cell and cancer biology, with significant implications for current and future therapies. Dr. Bissell's work has generated a fundamental and translationally crucial paradigm shift in our understanding of both normal and malignant tissues.

Her findings have had profound implications for cancer therapy by demonstrating that tumor cells can be influenced by their environment and are not just the product of their genetic mutations. For example, cells from the mammary glands grown in two-dimensional tissue cultures rapidly lose their identity, but once placed in proper three-dimensional microenvironments, they regain mammary form and function. This work presages the current excitement about generation of 3D tissue organoids and demonstrates Dr. Bissell's creative and innovative approach to science.

Dr. Elaine FuchsHoward Hughes Medical Institute Investigator and Rebecca C. Lancefield Professor and Head of the Robin Chemers Neustein Laboratory of Mammalian Cell Biology and Cell Biology; The Rockefeller University, New York, NY, USA

Awarded"For her studies elucidating the role of tissue stem cells in homeostasis, wound repair, inflammation and cancer."

The Work: Dr. Fuchs has used skin to study how the tissues of our body are able to replace dying cells and repair wounds. The skin must replenish itself constantly to protect against dehydration and harmful microbes. In her research, Fuchs showed that this is accomplished by a resident population of adult stem cells that continually generates a shell of indestructible cells that cover our body surface.

In her early research, Fuchs identified the proteins---keratinsthat produce the iron framework of the skin's building blocks, and showed that mutations in keratins are responsible for a group of blistering diseases in humans. In her later work, Fuchs identified the signals that prompt skin stem cells to make tissue and when to stop. In studying these processes, Fuchs learned that cancers hijack the fundamental mechanisms that tissue stem cells use to repair wounds. Her team pursued this parallel and isolated and characterized the malignant stem cells that are responsible for propagating a type of cancer called "squamous cell carcinoma." In her most recent work, she showed that these cells can be resistant to chemotherapies and immunotherapies and lead to tumor relapse.

The Impact: All tissues of our body must be able to replace dying cells and repair local wounds. Skin is particularly adept at performing these tasks. The identification and characterization of the resident skin stem cells that make and replenish the epidermis, sweat glands and hair provide important insights into this fountain of youth process and hold promise for regenerative medicine and aging. In normal tissues, the self-renewing ability of stem cells to proliferate is held in check by local inhibitory signals coming from the stem cells' neighbours. In injury, stimulatory signals mobilize the stem cells to proliferate and repair the wound. In aging, these normal balancing cues are tipped in favour of quiescence. In inflammatory disorders, stem cells become hyperactivated. In cancers, the wound mechanisms to mobilize stem cells are hijacked, leading to uncontrolled tissue growth. Understanding the basic mechanisms controlling stem cells in their native tissue is providing new strategies for searching out refractory tumor cells in cancer and for restoring normalcy in inflammatory conditions.

2020 John Dirks Canada Gairdner Global Health AwardThe 2020 John Dirks Canada Gairdner Global Health Award laureate is recognized for outstanding achievements in global health research:

Professor Salim S. Abdool KarimDirector of CAPRISA (Centre for the AIDS Program of Research in South Africa), the CAPRISA Professor in Global Health at Columbia University, New York and Pro Vice-Chancellor (Research) at the University of KwaZulu-Natal, Durban, South Africa

Professor Quarraisha Abdool KarimAssociate Scientific Director of CAPRISA, Professor in Clinical Epidemiology, Columbia University, New York and Professor in Public Health at the Nelson Mandela Medical School and Pro Vice-Chancellor (African Health) at the University of KwaZulu-Natal, Durban, South Africa

Awarded"For their discovery that antiretrovirals prevent sexual transmission of HIV, which laid the foundations for pre-exposure prophylaxis (PrEP), the HIV prevention strategy that is contributing to the reduction of HIV infection in Africa and around the world."

The Work: UNAIDS estimates that 37 million people were living with HIV and 1.8 million people acquired HIV in 2017. In Africa, which has over two thirds of all people with HIV, adolescent girls and young women have the highest rates of new HIV infections. ABC (Abstinence, Be faithful, and use Condoms) prevention messages have had little impact - due to gender power imbalances, young women are often unable to successfully negotiate condom use, insist on mutual monogamy, or convince their male partners to have an HIV test.

In responding to this crisis, Salim and Quarraisha Abdool Karim started investigating new HIV prevention technologies for women about 30 years ago. After two unsuccessful decades, their perseverance paid off when they provided proof-of-concept that antiretrovirals prevent sexually acquired HIV infection in women. Their ground-breaking CAPRISA 004 trial showed that tenofovir gel prevents both HIV infection and genital herpes. The finding was ranked inthe "Top 10 Scientific Breakthroughs of 2010" by the journal, Science. The finding was heralded by UNAIDS and the World Health Organization (WHO) as one of the most significant scientific breakthroughs in AIDS and provided the first evidence for what is today known as HIV pre-exposure prophylaxis (PrEP).

The Abdool Karims have also elucidated the evolving nature of the HIV epidemic in Africa, characterising the key social, behavioural and biological risk factors responsible for the disproportionately high HIV burden in young women. Their identification of the "Cycle of HIV Transmission", where teenage girls acquire HIV from men about 10 years older on average, has shaped UNAIDS policies on HIV prevention in Africa.

The impact: CAPRISA 004 and several clinical trials of oral tenofovir led tothe WHO recommending a daily tenofovir-containing pill for PrEP as a standard HIV prevention tool for all those at high risk a few years later. Several African countries are among the 68 countries across all continents that are currently making PrEP available for HIV prevention. The research undertaken in Africa by this South African couple has played a key role in shaping the local and global response to the HIV epidemic.

2020 Canada Gairdner Wightman AwardThe 2020 Canada Gairdner Wightman Award laureate is a Canadian scientist recognized for outstanding leadership in medicine and medical science throughout their career:

Dr. Guy Rouleau Director of the Montreal Neurological Institute-Hospital (The Neuro); Professor & Chair of the Department of Neurology and Neurosurgery, McGill University; Director of the Department of Neuroscience, McGill University Health Center

Awarded "For identifying and elucidating the genetic architecture of neurological and psychiatric diseases, including ALS, autism and schizophrenia, and his leadership in the field of Open Science."

The Work: Dr. Rouleau has identified over 20 genetic risk factors predisposing to a range of brain disorders, both neurological and psychiatric, involving either neurodevelopmental processes or degenerative events. He has defined a novel disease mechanism for diseases related to repeat expansions that are at play in some of the most severe neurodegenerative conditions. He has significantly contributed to the understanding of the role of de novo variants in autism and schizophrenia. In addition, he has made important advances for various neuropathies, in particular for amyotrophic lateral sclerosis (ALS) where he was involved in the identification of the most prevalent genetic risk factors -which in turn are now the core of innumerable ALS studies worldwide.

Dr. Rouleau has also played a pioneering role in the practice of Open Science (OS), transforming the Montreal Neurological Institute-Hospital (The Neuro) into the first OS institution in the world. The Neuro now uses OS principles to transform research and careand accelerate the development of new treatments for patients through Open Access, Open Data, Open Biobanking, Open Early Drug Discovery and non-restrictive intellectual property.

The Impact: The identification of genetic risk factors has a number of significant consequences. First, allowing for more accurate genetic counselling, which reduces the burden of disease to affected individuals, parents and society. A revealing case is Andermann syndrome, a severe neurodevelopmental and neurodegenerative condition that was once relatively common in the Saguenay-Lac-St-Jean region of Quebec. Now this disease has almost disappeared from that population. Second, identifying the causative gene allows the development of treatments. For instance, his earlier work on a form of ALS linked to the superoxide dismutase-1 gene (SOD1) opened up studies which are now the focal point of phase 2 clinical studies showing great promise.

Byactingasalivinglabforthelast coupleofyears,TheNeuroisspearheading the practice of OpenScience (OS).TheNeurois alsoengagingstakeholdersacross Canadawiththegoal of formalizinganational OSallianceforthe neurosciences.Dr.Rouleau'sworkinOScontributesfundamentallytothetransformationoftheveryecosystemofsciencebystimulatingnewthinkingandfosteringcommunitiesofsharing.InspiredbyTheNeuro'svision,theglobalsciencecommunityisreflecting oncurrentresearchconventionsandcollaborativeprojects,andthemomentumforOSisgainingafootholdinorganizationsandinstitutionsinallcornersoftheearth.

About the Gairdner Foundation:

The Gairdner Foundation was established in 1957 by Toronto stockbroker, James Gairdner to award annual prizes to scientists whose discoveries have had major impact on scientific progress and on human health. Since 1959 when the first awards were granted, 387scientists have received a Canada Gairdner Award and 92 to date have gone on to receive the Nobel Prize.The Canada Gairdner Awards promote a stronger culture of research and innovation across the country through our Outreach Programs including lectures and research symposia. The programs bring current and past laureates to a minimum of 15 universities across Canada to speak with faculty, trainees and high school students to inspire the next generation of researchers. Annual research symposia and public lectures are organized across Canada to provide Canadians access to leading science through Gairdner's convening power.

http://www.gairdner.org

SOURCE Gairdner Foundation

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/March2020/31/c7291.html

Go here to see the original:
2020 Canada Gairdner Awards Recognize World-renowned Scientists for Transformative Contributions to Research That Impact Human Health - Benzinga

Read More...

Renal Insufficiency May Be Associated With Impaired Regenerative Capacity in CAD – The Cardiology Advisor

Wednesday, April 1st, 2020

The following article is part of conference coverage from the American College of Cardiology (ACC.20) /World Congress of Cardiology. The Cardiology Advisors staff is reporting on research conducted by leading experts in cardiology. Check back for the latest news from the ACC.20.

Renal insufficiency may be linked to reduced circulating progenitor cell (CPC) counts, a factor indicative of impaired regenerative capacity in older adults with coronary artery disease (CAD), according to study results intended to be presented at the annual meeting of the American College of Cardiology (ACC 2020).

Anurag Mehta, MBBS, from the Emory University School of Medicine, Atlanta, Georgia, and colleagues estimated the number of CPCs with flow cytometry. CPCs were CD45med+ cells with a single nucleus expressing epitopes for CD34 and CD133. The samples of 1281 patients with CAD (mean age, 66 years; 39% women; 21% black) were analyzed. The association between renal insufficiency (ie, estimated glomerular filtration rate <60 mL/min/1.73 m2) and log-transformed CPC counts was examined using adjusted linear regression models. Furthermore, using adjusted Cox models, the investigators assessed the predictive value of CPC counts for cardiovascular death or myocardial infarction during a 3.5-year median follow-up period.

In unadjusted analyses renal insufficiency wasfound to be associated with lower counts of CD34+ cells (-10.1%; 95%CI, -16.9% to -2.8%; P =.008) and withlower counts of CD34+/CD133+ cells (-11.4%; 95% CI,-19.4% to -2.6%; P =.13) in 446patients.

After adjusting for age, renal insufficiencywas independently associated with lower counts of CD34+ cells (14.5%;95% CI, -24.4% to -3.4%; P =.012) andwith lower counts of CD34+/CD133+ cells (-15.7%; 95% CI,-28.7% to -0.4%; P =.045) in patients70 years. Patients with renal insufficiency who had counts below the medianfor CD34+ or CD34+/CD133+ cells were found tobe at a higher risk for adverse events (adjusted hazard ratio, 1.76; 95% CI,1.24-2.52 and adjusted hazard ratio, 1.80; 95% CI, 1.26-2.56, respectively).Notably, patients with renal insufficiency and CPC counts above the medianvalue had a similar risk for cardiovascular death or myocardial infarctioncompared with patients without renal insufficiency.

The investigators concluded, Impairedregenerative capacity in patients with CAD and [renal insufficiency] independentlypredicts cardiovascular risk.

Reference

Mehta A, Tahhan AS, Liu C, et al. Impaired regenerative capacity predicts outcomes in patients with coronary artery disease and renal insufficiency. Intended to be presented at: American College of Cardiology 69th Annual Scientific Session; March 28-30, 2020; Chicago, IL. Presentation 915-07. Accessed March 24, 2020.

Visit The Cardiology Advisors conference section for coverage intended to be presented at the annual meeting of the American College of Cardiology (ACC.20)/World Congress of Cardiology

See the original post:
Renal Insufficiency May Be Associated With Impaired Regenerative Capacity in CAD - The Cardiology Advisor

Read More...

Clinical Outcomes Of Mesoblast’s Cell Therapy In End-stage Ischemic Heart Failure Presented At American College Of Cardiology Virtual Scientific…

Tuesday, March 31st, 2020

NEW YORK, March 30, 2020 (GLOBE NEWSWIRE) -- Results from a sub-study of 70 patients with end-stage ischemic heart failure and a Left Ventricular Assist Device (LVAD), of 159 randomized patients who received either Mesoblasts allogeneic mesenchymal precursor cell (MPC) product candidate Revascor or saline, were presented on March 28 at the American College of Cardiology (ACC) Virtual Scientific Sessions. The full results from these 70 patients will be published in a peer-reviewed journal.

When compared to controls, in MPC recipients:

The conclusions were:

End-stage ischemic heart failure patients with LVADs are older and have co-morbidities such as diabetes, thereby closely resembling the majority of patients in Mesoblasts 566-patient Phase 3 trial for advanced chronic heart failure, planned to readout in mid-2020.

Revascor is being developed for use in end-stage ischemic heart failure patients with LVADs under existing FDA Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug Designations.

About Mesoblast Mesoblast Limited (Nasdaq:MESO; ASX:MSB) is a world leader in developing allogeneic (off-the-shelf) cellular medicines. The Company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of commercial products and late-stage product candidates. Mesoblasts proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.

Mesoblast has filed a Biologics License Application to the United States Food and Drug Administration (FDA) to seek approval of its product candidate RYONCIL (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GvHD). Remestemcel-L is also being developed for other rare diseases. Mesoblast is completing Phase 3 trials for its product candidates for advanced heart failure and chronic low back pain. If approved, RYONCIL is expected to be launched in the United States in 2020 for pediatric steroid-refractory acute GVHD. Two products have been commercialized in Japan and Europe by Mesoblasts licensees, and the Company has established commercial partnerships in Europe and China for certain Phase 3 assets.

Mesoblast has a strong and extensive global intellectual property (IP) portfolio with protection extending through to at least 2040 in all major markets. This IP position is expected to provide the Company with substantial commercial advantages as it develops its product candidates for these conditions.

Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see http://www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast

Forward-Looking Statements This announcement includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward- looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward- looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about the timing, progress and results of Mesoblasts preclinical and clinical studies; Mesoblasts ability to advance product candidates into, enroll and successfully complete, clinical studies; the timing or likelihood of regulatory filings and approvals; and the pricing and reimbursement of Mesoblasts product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblasts actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

Release authorized by the Chief Executive.

For further information, please contact:

See the article here:
Clinical Outcomes Of Mesoblast's Cell Therapy In End-stage Ischemic Heart Failure Presented At American College Of Cardiology Virtual Scientific...

Read More...

Covington-based CTI partners with Humanigen for study of Lenzilumab for treatment of Coronavirus – User-generated content

Tuesday, March 31st, 2020

Covington-based CTIClinical Trial and Consulting Services has partnered with California-based Humanigen, Inc. on a study for the treatment of novel coronavirus 2019 (COVID-19).

Humanigen, Inc., (HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on preventing and treating cytokine storm with lenzilumab, the companys proprietary Humaneered anti-human-granulocyte-macrophage colony-stimulating factor (GM-CSF) monoclonal antibody, announced that the company has submitted an initial protocol synopsis to the FDA in support of the companys plans to initiate a multi-center, US, Phase III study in COVID-19 patients.

The study, if approved, will be a randomized, controlled, clinical trial with lenzilumab for the prevention of ARDS and/or death in hospitalized patients with pneumonia associated with coronavirus 2 (SARS-CoV-2) infection in COVID-19.

The study will be conducted in partnership with CTI, which specializes in complex programs for critically and chronically ill patients.

Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms.

Humanigen has pioneered the field of GM-CSF neutralization and, unlike others, has already conducted two Phase I and two Phase II studies, including in patients with severe respiratory conditions, with excellent safety results, said Dr. Cameron Durrant, chief executive officer of Humanigen. We have been working on prevention of cytokine storm for nearly three years. Lenzilumab has an excellent safety and tolerability profile and has not been associated with serious adverse events, including in patients who are immunosuppressed or with severe asthma. Subject to discussion and agreement with regulatory authorities, we intend to progress as quickly as possible with this study.

More details on the companys programs in COVID-19 can be found on the companys websiteunder the COVID-19 tab.

CTI Clinical Trial and Consulting Services is a global, privately held, full-service contract research organization (CRO).

It delivers a complete spectrum of clinical trial and consulting services throughout the lifecycle of development, from concept to commercialization.

CTIs focused therapeutic approach provides pharmaceutical, biotechnology, and medical device firms with clinical and disease area expertise in rare diseases, regenerative medicine/gene therapy, immunology, transplantation, nephrology, hematology/oncology, neurology, infectious diseases, hepatology, cardiopulmonary, and pediatric populations.

Schroeder

The COVID-19 pandemic demands an unprecedented response from the pharmaceutical and biotechnology communities, requiring innovation, collaboration, and prioritization of speed without the cost of safety, remarked Tim Schroeder, founder and CEO of CTI. We are proud to have the opportunity to collaborate on such a response with the Humanigen team and to work together to develop an effective treatment solution for those hardest hit by COVID-19.

CTI also offers a fully integrated multi-specialty clinical research site that conducts phase I-IV trials. CTI has a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. With clinical trial experience across 6 continents, CTI partners with research sites, patients, and sponsors to fulfill unmet medical needs. CTI is headquartered in the Greater Cincinnati, OH area, with operations across North America, Europe, Latin America, and Asia-Pacific.

For more information on CTI, click here.

Study to tackle leading cause of death in COVID-19 patients

Lenzilumab, a monoclonal antibody that neutralizes granulocyte macrophage colony stimulating factor (GM-CSF)

GM-CSF is up-regulated in COVID-19 patients and may cause a harmful immune response leading to acute respiratory distress syndrome (ARDS)

Clinical evidence suggests that this harmful immune response contributes to cytokine storm in COVID-19 patients at risk of developing ARDS

Company plans to study lenzilumab in COVID-19 patients to prevent ARDS and mortality with CTI Clinical Trial and Consulting Services (CTI)

COVID-19 is an infectious disease caused by SARS-CoV-2. COVID-19 has become a global pandemic, with over 460,000 confirmed cases and over 21,000 deaths reported to date. Patients with severe cases of COVID-19 experience severe viral pneumonia that can progress to acute respiratory distress syndrome (ARDS) and death.

ARDS is an acute, life-threatening inflammatory lung injury characterized by hypoxia a lack of oxygen to the tissue and stiff lungs due to increased pulmonary vascular permeability. ARDS necessitates hospitalization and mechanical ventilation. A rapid increase in patients with ARDS presents a major challenge for the global public health system given limited hospital beds and ventilators. When implementing standard of care, including mechanical ventilation, ARDS has an overall mortality rate of greater than 40 percent.

Humanigen, Inc. study is focused on the belief that its GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection as well as the serious and potentially life-threatening CAR-T therapy-related side effects while preserving and potentially improving the efficacy of the CAR-T therapy itself, thus breaking the efficacy/toxicity linkage.

The companys immediate focus is to prevent or minimize the cytokine storm that precedes severe lung dysfunction and ARDS in cases of pneumonia-associated SARS-CoV-2 infection and also in combining FDA-approved and development stage CAR-T therapies with lenzilumab, the companys proprietary Humaneered anti-human-GM-CSF immunotherapy, which is its lead product candidate.

CTI

Originally posted here:
Covington-based CTI partners with Humanigen for study of Lenzilumab for treatment of Coronavirus - User-generated content

Read More...

2020 Canada Gairdner Awards Recognize World-renowned Scientists for Transformative Contributions to Research That Impact Human Health – Yahoo Finance

Tuesday, March 31st, 2020

TORONTO , March 31, 2020 /CNW/ - The Gairdner Foundation is pleased to announce the 2020 Canada Gairdner Award laureates, recognizing some of the world's most significant biomedical research and discoveries. During these challenging times, we believe it is important to celebrate scientists and innovators from around the world and commend them for their tireless efforts to conduct research that impacts human health.

2020 Canada Gairdner International AwardThe five 2020 Canada Gairdner International Award laureates are recognized for seminal discoveries or contributions to biomedical science:

Dr. Masatoshi Takeichi Senior Visiting Scientist, RIKEN Center for Biosystems Dynamics Research, Kobe, Japan ; Professor Emeritus, Kyoto University , Kyoto, Japan

Dr. Rolf Kemler Emeritus Member and Director, Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany

Awarded "For their discovery, characterization and biology of cadherins and associated proteins in animal cell adhesion and signalling."

Dr. Takeichi

The Work: The animal body is made up of numerous cells. Dr. Takeichi was investigatinghow animal cells stick together to form tissues and organs, and identified a key protein which he named 'cadherin'.Cadherin is present on the surface of a cell and binds to the same cadherin protein on the surface of another cell through like-like interaction, thereby binding the cells together. Without cadherin, cell to cell adhesion becomes weakened and leads to the disorganization of tissues. Dr. Takeichi found that there are multiple kinds of cadherin within the body, each of which are made by different cell types, such as epithelial and neuronal cells. Cells with the same cadherins tend to cluster together, explaining the mechanism of how different cells are sorted out and organized to form functional organs.

Further studies by Dr. Takeichi's group showed that cadherin function is supported by a number of cytoplasmic proteins, includingcatenins, and their cooperation is essential for shaping of tissues. His studies also revealed that the cadherin-dependent adhesion mechanism is involved in synaptic connections between neurons, which are important for brain wiring.

Dr. Kemler

The Work: Dr. Kemler, using an immunological approach, developed antibodies directed against surface antigens of early mouse embryos. These antibodies were shown to prevent compaction of the mouse embryo and interfered with subsequent development. Both Dr. Kemler and Dr. Takeichi went on to clone and sequence the gene encoding E-cadherin and demonstrate that it was governing homophilic cell adhesion.

Dr. Kemler also discovered the other proteins that interact with the cadherins, especially the catenins, to generate the machinery involved in animal cell-to-cell adhesion. This provided the first evidence of their importance in normal development and diseases such as cancer. It has been discovered that cadherins and catenins are correlated to the formation and growth of some cancers and how tumors continue to grow. Beta catenin is linked to cell adhesion through interaction with cadherins but is also a key component of the Wnt signalling pathway that is involved in normal development and cancer. There are approximately 100 types of cadherins, known as the cadherin superfamily.

Dr. Takeichi

The Impact: The discovery of cadherins, which are found in all multicellular animalspecies, has allowed us to interpret how multicellular systems are generated and regulated. Loss of cadherin function has been implicated as the cause of certain cancers, as well as in invasiveness of many cancers. Mutations in special types of cadherin result in neurological disorders, such as epilepsy and hearing loss. The knowledge of cadherin function is expected to contribute to the development of effective treatments against such diseases.

Dr. Kemler

The Impact: Human tumors are often of epithelial origin. Given the role of E-cadherin for the integrity of an epithelial cell layer, the protein can be considered as a suppressor of tumor growth. The research on the cadherin superfamily has had great impact on fields as diverse as developmental biology, cell biology, oncology, immunology and neuroscience. Mutations in cadherins/catenins are frequently found in tumors. Various screens are being used to identify small molecules that might restore cell adhesion as a potential cancer therapy.

Dr. Roel Nusse Professor & Chair, Department of Developmental Biology; Member, Institute for StemCell Biology andRegenerativeMedicine, Stanford University , School of Medicine. Virginia and Daniel K. Ludwig Professor of Cancer Research. Investigator, Howard Hughes Medical Institute

Awarded"For pioneering work on the Wnt signaling pathway and its importance in development, cancer and stem cells"

The Work: Dr. Nusse's research has elucidated the mechanism and role of Wnt signaling, one of the most important signaling systems in development. There is now abundant evidence that Wnt signaling is active in cancer and in control of proliferation versus differentiation of adult stem cells, making the Wnt pathway one of the paradigms for the fundamental connections between normal development and cancer.

Among Dr. Nusse's contributions is the original discovery of the first Wnt gene (together with Harold Varmus) as an oncogene in mouse breast cancer. Afterwards Dr. Nusse identified the Drosophila Wnt homolog as a key developmental gene, Wingless. This led to the general realization of the remarkable links between normal development and cancer, now one of the main themes in cancer research. Using Drosophila genetics, he established the function of beta-catenin as a mediator of Wnt signaling and the Frizzleds as Wnt receptors (with Jeremy Nathans ), thereby establishing core elements of what is now called the Wnt pathway. A major later accomplishment of his group was the first successful purification of active Wnt proteins, showing that they are lipid-modified and act as stem cell growth factors.

The Impact: Wnt signaling is implicated in the growth of human embryos and the maintenance of tissues. Consequently, elucidating the Wnt pathway is leading to deeper insights into degenerative diseases and the development of new therapeutics. The widespread role of Wnt signaling in cancer is significant for the treatment of the disease as well. Isolating active Wnt proteins has led to the use of Wnts by researchers world-wide as stem cell growth factors and the expansion of stem cells into organ-like structures (organoids).

Dr. Mina J. Bissell Distinguished Senior Scientist, Biological Systems and Engineering Division, Lawrence Berkeley National Laboratory; Faculty; Graduate Groups in Comparative Biochemistry, Endocrinology, Molecular Toxicology and Bioengineering, University of California Berkeley , Berkeley, CA , USA

Awarded "For characterizing "Dynamic Reciprocity" and the significant role that extracellular matrix (ECM) signaling and microenvironment play in gene regulation in normal and malignant cells, revolutionizing the fields of oncology and tissue homeostasis."

The Work: Dr. Mina Bissell's career has been driven by challenging established paradigms in cellular and developmental biology. Through her research, Dr. Bissell showed that tissue architecture plays a dominant role in determining cell and tissue phenotype and proposed the model of 'dynamic reciprocity' (DR) between the extracellular matrix (ECM) and chromatin within the cell nucleus. Dynamic reciprocity refers to the ongoing, bidirectional interaction between cells and their microenvironment. She demonstrated that the ECM could regulate gene expression just as gene expression could regulate ECM, and that these two phenomena could occur concurrently in normal or diseased tissue.

She also developed 3D culture systems to study the interaction of the microenvironment and tissue organization and growth, using the mammary gland as a model.

The Impact:Dr. Bissell's model of dynamic reciprocity has been proven and thoroughly established since its proposal three decades ago and the implications have permeated every area of cell and cancer biology, with significant implications for current and future therapies. Dr. Bissell's work has generated a fundamental and translationally crucial paradigm shift in our understanding of both normal and malignant tissues.

Her findings have had profound implications for cancer therapy by demonstrating that tumor cells can be influenced by their environment and are not just the product of their genetic mutations. For example, cells from the mammary glands grown in two-dimensional tissue cultures rapidly lose their identity, but once placed in proper three-dimensional microenvironments, they regain mammary form and function. This work presages the current excitement about generation of 3D tissue organoids and demonstrates Dr. Bissell's creative and innovative approach to science.

Dr. Elaine Fuchs Howard Hughes Medical Institute Investigator and Rebecca C. Lancefield Professor and Head of the Robin Chemers Neustein Laboratory of Mammalian Cell Biology and Cell Biology; The Rockefeller University , New York, NY , USA

Awarded"For her studies elucidating the role of tissue stem cells in homeostasis, wound repair, inflammation and cancer."

The Work: Dr. Fuchs has used skin to study how the tissues of our body are able to replace dying cells and repair wounds. The skin must replenish itself constantly to protect against dehydration and harmful microbes. In her research, Fuchs showed that this is accomplished by a resident population of adult stem cells that continually generates a shell of indestructible cells that cover our body surface.

In her early research, Fuchs identified the proteins---keratinsthat produce the iron framework of the skin's building blocks, and showed that mutations in keratins are responsible for a group of blistering diseases in humans. In her later work, Fuchs identified the signals that prompt skin stem cells to make tissue and when to stop. In studying these processes, Fuchs learned that cancers hijack the fundamental mechanisms that tissue stem cells use to repair wounds. Her team pursued this parallel and isolated and characterized the malignant stem cells that are responsible for propagating a type of cancer called "squamous cell carcinoma." In her most recent work, she showed that these cells can be resistant to chemotherapies and immunotherapies and lead to tumor relapse.

The Impact: All tissues of our body must be able to replace dying cells and repair local wounds. Skin is particularly adept at performing these tasks. The identification and characterization of the resident skin stem cells that make and replenish the epidermis, sweat glands and hair provide important insights into this fountain of youth process and hold promise for regenerative medicine and aging. In normal tissues, the self-renewing ability of stem cells to proliferate is held in check by local inhibitory signals coming from the stem cells' neighbours. In injury, stimulatory signals mobilize the stem cells to proliferate and repair the wound. In aging, these normal balancing cues are tipped in favour of quiescence. In inflammatory disorders, stem cells become hyperactivated. In cancers, the wound mechanisms to mobilize stem cells are hijacked, leading to uncontrolled tissue growth. Understanding the basic mechanisms controlling stem cells in their native tissue is providing new strategies for searching out refractory tumor cells in cancer and for restoring normalcy in inflammatory conditions.

2020 John Dirks Canada Gairdner Global Health AwardThe 2020 John Dirks Canada Gairdner Global Health Award laureate is recognized for outstanding achievements in global health research:

Professor Salim S. Abdool Karim Director of CAPRISA (Centre for the AIDS Program of Research in South Africa), the CAPRISA Professor in Global Health at Columbia University , New York and Pro Vice-Chancellor (Research) at the University of KwaZulu-Natal, Durban, South Africa

Professor Quarraisha Abdool KarimAssociate Scientific Director of CAPRISA, Professor in Clinical Epidemiology, Columbia University , New York and Professor in Public Health at the Nelson Mandela Medical School and Pro Vice-Chancellor (African Health) at the University of KwaZulu-Natal, Durban, South Africa

Awarded"For their discovery that antiretrovirals prevent sexual transmission of HIV, which laid the foundations for pre-exposure prophylaxis (PrEP), the HIV prevention strategy that is contributing to the reduction of HIV infection in Africa and around the world."

The Work: UNAIDS estimates that 37 million people were living with HIV and 1.8 million people acquired HIV in 2017. In Africa, which has over two thirds of all people with HIV, adolescent girls and young women have the highest rates of new HIV infections. ABC (Abstinence, Be faithful, and use Condoms) prevention messages have had little impact - due to gender power imbalances, young women are often unable to successfully negotiate condom use, insist on mutual monogamy, or convince their male partners to have an HIV test.

In responding to this crisis, Salim and Quarraisha Abdool Karim started investigating new HIV prevention technologies for women about 30 years ago. After two unsuccessful decades, their perseverance paid off when they provided proof-of-concept that antiretrovirals prevent sexually acquired HIV infection in women. Their ground-breaking CAPRISA 004 trial showed that tenofovir gel prevents both HIV infection and genital herpes. The finding was ranked inthe "Top 10 Scientific Breakthroughs of 2010" by the journal, Science. The finding was heralded by UNAIDS and the World Health Organization (WHO) as one of the most significant scientific breakthroughs in AIDS and provided the first evidence for what is today known as HIV pre-exposure prophylaxis (PrEP).

The Abdool Karims have also elucidated the evolving nature of the HIV epidemic in Africa , characterising the key social, behavioural and biological risk factors responsible for the disproportionately high HIV burden in young women. Their identification of the "Cycle of HIV Transmission", where teenage girls acquire HIV from men about 10 years older on average, has shaped UNAIDS policies on HIV prevention in Africa .

The impact: CAPRISA 004 and several clinical trials of oral tenofovir led tothe WHO recommending a daily tenofovir-containing pill for PrEP as a standard HIV prevention tool for all those at high risk a few years later. Several African countries are among the 68 countries across all continents that are currently making PrEP available for HIV prevention. The research undertaken in Africa by this South African couple has played a key role in shaping the local and global response to the HIV epidemic.

2020 Canada Gairdner Wightman AwardThe 2020 Canada Gairdner Wightman Award laureate is a Canadian scientist recognized for outstanding leadership in medicine and medical science throughout their career:

Dr. Guy Rouleau Director of the Montreal Neurological Institute-Hospital (The Neuro); Professor & Chair of the Department of Neurology and Neurosurgery, McGill University ; Director of the Department of Neuroscience, McGill University Health Center

Awarded "For identifying and elucidating the genetic architecture of neurological and psychiatric diseases, including ALS, autism and schizophrenia, and his leadership in the field of Open Science."

The Work: Dr. Rouleau has identified over 20 genetic risk factors predisposing to a range of brain disorders, both neurological and psychiatric, involving either neurodevelopmental processes or degenerative events. He has defined a novel disease mechanism for diseases related to repeat expansions that are at play in some of the most severe neurodegenerative conditions. He has significantly contributed to the understanding of the role of de novo variants in autism and schizophrenia. In addition, he has made important advances for various neuropathies, in particular for amyotrophic lateral sclerosis (ALS) where he was involved in the identification of the most prevalent genetic risk factors -which in turn are now the core of innumerable ALS studies worldwide.

Dr. Rouleau has also played a pioneering role in the practice of Open Science (OS), transforming the Montreal Neurological Institute-Hospital (The Neuro) into the first OS institution in the world. The Neuro now uses OS principles to transform research and careand accelerate the development of new treatments for patients through Open Access, Open Data, Open Biobanking, Open Early Drug Discovery and non-restrictive intellectual property.

The Impact: The identification of genetic risk factors has a number of significant consequences. First, allowing for more accurate genetic counselling, which reduces the burden of disease to affected individuals, parents and society. A revealing case is Andermann syndrome, a severe neurodevelopmental and neurodegenerative condition that was once relatively common in the Saguenay-Lac-St-Jean region of Quebec . Now this disease has almost disappeared from that population. Second, identifying the causative gene allows the development of treatments. For instance, his earlier work on a form of ALS linked to the superoxide dismutase-1 gene (SOD1) opened up studies which are now the focal point of phase 2 clinical studies showing great promise.

Byactingasalivinglabforthelast coupleofyears,TheNeuroisspearheading the practice of OpenScience (OS).TheNeurois alsoengagingstakeholdersacross Canadawiththegoal of formalizinganational OSallianceforthe neurosciences.Dr.Rouleau'sworkinOScontributesfundamentallytothetransformationoftheveryecosystemofsciencebystimulatingnewthinkingandfosteringcommunitiesofsharing.InspiredbyTheNeuro'svision,theglobalsciencecommunityisreflecting oncurrentresearchconventionsandcollaborativeprojects,andthemomentumforOSisgainingafootholdinorganizationsandinstitutionsinallcornersoftheearth.

About the Gairdner Foundation:

The Gairdner Foundation was established in 1957 by Toronto stockbroker, James Gairdner to award annual prizes to scientists whose discoveries have had major impact on scientific progress and on human health. Since 1959 when the first awards were granted, 387scientists have received a Canada Gairdner Award and 92 to date have gone on to receive the Nobel Prize.The Canada Gairdner Awards promote a stronger culture of research and innovation across the country through our Outreach Programs including lectures and research symposia. The programs bring current and past laureates to a minimum of 15 universities across Canada to speak with faculty, trainees and high school students to inspire the next generation of researchers. Annual research symposia and public lectures are organized across Canada to provide Canadians access to leading science through Gairdner's convening power.

http://www.gairdner.org

SOURCE Gairdner Foundation

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/March2020/31/c7291.html

Read more from the original source:
2020 Canada Gairdner Awards Recognize World-renowned Scientists for Transformative Contributions to Research That Impact Human Health - Yahoo Finance

Read More...

IP : Tissue Regenix Group plc – Update in relation to working capital position and impact of COVID-19 pandemic – Marketscreener.com

Tuesday, March 31st, 2020

Tissue Regenix Group (AIM:TRX) ('Tissue Regenix' or the 'Company') the regenerative medical devices company, today provides an update in relation to its working capital position and an initial assessment of the impact to its business following the outbreak of COVID-19.

Following the trading update announced on 22 January 2020, Tissue Regenix has successfully implemented various cost control measures, resulting in the Board's belief that the Company's available cash runway will now continue to support its working capital requirements until at least the end of the second week of May 2020.

As previously announced, the Board is endeavouring to secure necessary funding for the Company. The Board is encouraged by a number of ongoing discussions with potential investors which the Board is working to conclude in the near future. However, there is no guarantee that any such discussions will result in near-term funding being made available to the Company. Should this funding not be forthcoming before the Company's available cash runway expires (not expected by the Board to be before the end of the second week of May) then the Board will be required to take action to protect the interests of creditors and which, if necessary, is likely to result in a material reduction in any resulting value attributable to shareholders.

COVID-19

Further announcements will be made at the appropriate time.

For more Information

The person responsible for this announcement is, Gareth Jones, Interim CEO.

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The company's patented decellularisation ('dCELL') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany.

In August 2017 Tissue Regenix acquired CellRight Technologies, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.

See more here:
IP : Tissue Regenix Group plc - Update in relation to working capital position and impact of COVID-19 pandemic - Marketscreener.com

Read More...

Global Regenerative Medicine Market 2019 Present Status and Future Opportunities by Major Companies Typs and Applications 2024 – The Fuel Fox

Tuesday, March 31st, 2020

The report on the Global Regenerative Medicine Market has been prepared after conducting a comprehensive research through a systematized methodology. These skills are useful for scrutinizing the market on the terms of outlined research guidelines. Mainly, global Regenerative Medicine market research report covers all the information about the target audience, manufactures, vendors, research papers, products and many more.

Request a sample of this report @ https://www.orbispharmareports.com/sample-request/13701

Keeping a focus on the overall market aspects, and perceptions, this report vastly covers profiles of the companies who have made it big in this particular field along with their sales data and other data. It also suggests the business models, innovations, growth and every information about the big manufacturers that will be present the future market estimates. Every market consists of set of manufacturers, vendors and consumers that gives a definition to the market, its each and every move, achievements. All these are the important subjects required to study the analysis of the global Regenerative Medicine market. It also includes the major market conditions across the globe such as the product profit, price, production, capacity, demand, supply, as well as market growth structure. In addition, this report offers significant data through the SWOT analysis, investment return data, and investment feasibility analysis.

Top Companies Analysis:

J & J (DePuy Synthes)MedtronicZimmerBiometStrykerAllergan(Acelity)MiMedx GroupOrganogenesisFujifilm Cellular DynamicsOsiris TherapeuticsVcanbioCCBCCytoriCelgeneVericel CorporationGuanhao BiotechMesoblastAMAG Pharmaceuticals (CBR)ViaCordCordLifeIntegra LifeSciencesNuvasiveCook BiotechJapan Tissue Engineering

Browse the complete report @ https://www.orbispharmareports.com/global-regenerative-medicine-market-2019-present-status-and-future-opportunities-by-major-companies-typs-and-applications-2024/

The global Regenerative Medicine market report also features a comprehensive quantitative and qualitative evaluation by analysing information collected from market experts and industry participants in the major points of the market value chain. The data offered in global Regenerative Medicine market report is gathered based on the latest industry news, trends, as well as opportunities. This study offers a separate analysis of the major trends in the existing market, mandates and regulations, micro & macroeconomic indicators is also comprised in this report. By doing so, the study estimated the attractiveness of every major segment during the prediction period.

Segmentation by Type:

Cell TherapyTissue EngineeringOthers

Segmentation by Application:

DermatologyCardiovascularCNSOrthopedicOthers

Moreover, the report comprises the analysis of opportunities available in the Regenerative Medicine market on the global level. It also includes the major market conditions across the globe such as the product profit, price, production, capacity, demand, supply, as well as market growth structure.The annual progression for the global Regenerative Medicine market in different regions cannot always be listed down as it will keep changing, thus studying and reviewing markets occasionally becomes vital. In addition, the Regenerative Medicine market report provides a detailed information about the key market players along with the strategies they implemented to gain market existence and develop themselves. The report includes precise market estimations depending on current market status and future market forecasts.

Make an enquiry of this report @ https://www.orbispharmareports.com/enquiry-before-buying/13701

About Us :

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us :

Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: +1 (972)-362-8199; +91 895 659 5155

Link:
Global Regenerative Medicine Market 2019 Present Status and Future Opportunities by Major Companies Typs and Applications 2024 - The Fuel Fox

Read More...

Regenerative Medicine Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2025 – Daily Science

Friday, March 27th, 2020

Regenerative Medicine Market: Snapshot

Regenerative medicine is a part of translational research in the fields of molecular biology and tissue engineering. This type of medicine involves replacing and regenerating human cells, organs, and tissues with the help of specific processes. Doing this may involve a partial or complete reengineering of human cells so that they start to function normally.

Get Sample Copy of the Report @https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1889

Regenerative medicine also involves the attempts to grow tissues and organs in a laboratory environment, wherein they can be put in a body that cannot heal a particular part. Such implants are mainly preferred to be derived from the patients own tissues and cells, particularly stem cells. Looking at the promising nature of stem cells to heal and regenerative various parts of the body, this field is certainly expected to see a bright future. Doing this can help avoid opting for organ donation, thus saving costs. Some healthcare centers might showcase a shortage of organ donations, and this is where tissues regenerated using patients own cells are highly helpful.

There are several source materials from which regeneration can be facilitated. Extracellular matrix materials are commonly used source substances all over the globe. They are mainly used for reconstructive surgery, chronic wound healing, and orthopedic surgeries. In recent times, these materials have also been used in heart surgeries, specifically aimed at repairing damaged portions.

Cells derived from the umbilical cord also have the potential to be used as source material for bringing about regeneration in a patient. A vast research has also been conducted in this context. Treatment of diabetes, organ failure, and other chronic diseases is highly possible by using cord blood cells. Apart from these cells, Whartons jelly and cord lining have also been shortlisted as possible sources for mesenchymal stem cells. Extensive research has conducted to study how these cells can be used to treat lung diseases, lung injury, leukemia, liver diseases, diabetes, and immunity-based disorders, among others.

Global Regenerative Medicine Market: Overview

The global market for regenerative medicine market is expected to grow at a significant pace throughout the forecast period. The rising preference of patients for personalized medicines and the advancements in technology are estimated to accelerate the growth of the global regenerative medicine market in the next few years. As a result, this market is likely to witness a healthy growth and attract a large number of players in the next few years. The development of novel regenerative medicine is estimated to benefit the key players and supplement the markets growth in the near future.

Global Regenerative Medicine Market: Key Trends

The rising prevalence of chronic diseases and the rising focus on cell therapy products are the key factors that are estimated to fuel the growth of the global regenerative medicine market in the next few years. In addition, the increasing funding by government bodies and development of new and innovative products are anticipated to supplement the growth of the overall market in the next few years.

On the flip side, the ethical challenges in the stem cell research are likely to restrict the growth of the global regenerative medicine market throughout the forecast period. In addition, the stringent regulatory rules and regulations are predicted to impact the approvals of new products, thus hampering the growth of the overall market in the near future.

Global Regenerative Medicine Market: Market Potential

The growing demand for organ transplantation across the globe is anticipated to boost the demand for regenerative medicines in the next few years. In addition, the rapid growth in the geriatric population and the significant rise in the global healthcare expenditure is predicted to encourage the growth of the market. The presence of a strong pipeline is likely to contribute towards the markets growth in the near future.

Global Regenerative Medicine Market: Regional Outlook

In the past few years, North America led the global regenerative medicine market and is likely to remain in the topmost position throughout the forecast period. This region is expected to account for a massive share of the global market, owing to the rising prevalence of cancer, cardiac diseases, and autoimmunity. In addition, the rising demand for regenerative medicines from the U.S. and the rising government funding are some of the other key aspects that are likely to fuel the growth of the North America market in the near future.

Furthermore, Asia Pacific is expected to register a substantial growth rate in the next few years. The high growth of this region can be attributed to the availability of funding for research and the development of research centers. In addition, the increasing contribution from India, China, and Japan is likely to supplement the growth of the market in the near future.

Request TOC of the Report @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=1889

Global Regenerative Medicine Market: Competitive Analysis

The global market for regenerative medicines is extremely fragmented and competitive in nature, thanks to the presence of a large number of players operating in it. In order to gain a competitive edge in the global market, the key players in the market are focusing on technological developments and research and development activities. In addition, the rising number of mergers and acquisitions and collaborations is likely to benefit the prominent players in the market and encourage the overall growth in the next few years.

Some of the key players operating in the regenerative medicine market across the globe areVericel Corporation, Japan Tissue Engineering Co., Ltd., Stryker Corporation, Acelity L.P. Inc. (KCI Licensing), Organogenesis Inc., Medtronic PLC, Cook Biotech Incorporated, Osiris Therapeutics, Inc., Integra Lifesciences Corporation, and Nuvasive, Inc.A large number of players are anticipated to enter the global market throughout the forecast period.

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Visit link:
Regenerative Medicine Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2025 - Daily Science

Read More...

Cumberland Medical & Purple Lotus Aesthetics Partner With Cyto CBD To Address Opioid Epidemic In North Carolina – The Mountaineer

Friday, March 27th, 2020

FAYETTEVILLE, N.C., March 26, 2020 /PRNewswire/ -- Cyto CBD, the CBD company that created precision medical dosing, is partnering with Cumberland Medical Associates and Purple Lotus Aesthetics to help transition patients from opioid-focused treatments to Cannabidiol (CBD) for chronic pain management.

A highly anticipated study, published in January 2020, in Postgraduate Medicine Journal showed that 53% of chronic pain patients that were on opioids for over a year at least were able to reduce their opioid usage and/or completely discontinue opioids with daily supplementation of CBD in just eight weeks. This is why Dr. Sanjiv Dalvi and his wife, Dr. Sumedha Dalvi, who are both certified Addiction and Regenerative Medicine Specialists, started integrating Cyto CBD into their practice at Cumberland Medical.

"The potential benefits of CBD are undeniable, as we are seeing more and more data to support its use in our chronic pain patients. Additionally, given the holistic nature of the product, we are seeing an improvement in overall quality of life, as patients are getting better sleep and experiencing lower stress levels," said Dr. Sanjiv Dalvi, MD, PhD. "We use Cyto CBD because it is a medical grade product with research to confirm its quality. The company owns the entire production chain, including the farm where the hemp is cultivated, and their pharmaceutical approach to quality gives us confidence in recommending it and using it with our patients."

Cumberland Medical focuses on holistic health, pain management, mental health and sleep medicine. The clinic now serves as a hub where patients can access Cyto CBD products through their team of specialists and/or by purchasing the products in office, for personal use.

"With all of the attention that CBD is getting, it is important to remember that this is a product that is ultimately being ingested or applied to our bodies. That is why CBD products should be no less than medical grade and the reason Cyto CBD is manufactured at facilities that are cGMP certified and fully registered with the FDA," said Dr. Cohin Kakar, Chief Marketing Officer of Cyto CBD. "We are thrilled to bring an alternative therapy to the community in North Carolina that we can confidently endorse as safe with high purity."

Cyto CBD is now available at Cumberland Medical and will be available at their upcoming partner practice, Purple Lotus Aesthetics, scheduled to open in the summer of 2020. To schedule an appointment or learn more, please contact Cumberland Medical at (910) 864-0689 or visit their practice located at 5085 Morganton Road, Suite 100, Fayetteville, NC 28314.

About Cyto CBD Headquartered in Los Angeles, California and part of The Anthos Group, Cyto CBD is exclusively available at clinics and pharmacies that focus on health and medical care. Cyto CBD has pharmacists and physicians on staff, endorsements from physicians all over the world, and they serve on the National Cannabis Industry Association (NCIA) Board. Cyto CBD also won the Global Health & Pharma Award for Most Innovative CBD Company in 2019. Cyto CBD is an educator in the industry, as the team hosts regular educational webinars, keeping the medical community updated and informed around new science in CBD and cannabinoids.

For more on Cyto CBD visit cytocbd.com, and follow on Facebook, Twitter, Instagram.

Go here to see the original:
Cumberland Medical & Purple Lotus Aesthetics Partner With Cyto CBD To Address Opioid Epidemic In North Carolina - The Mountaineer

Read More...

Non-Profit Offers Free Stem Cell Therapy to Veterans – Pain News Network

Friday, March 27th, 2020

By A. Rahman Ford, PNN Columnist

No group is more worthy of the revolutionary benefits of stem cell therapy than Americas military veterans. While the U.S. Department of Veterans Affairs (VA) thinks the field is in its infancy and much more research is needed before stem cells are offered as treatment, brave practitioners are stepping forward to help veterans NOW.

Dr. Joseph Kanan and his staff at the Tullahoma Chiropractic Center are providing free stem cell therapy for veterans who suffer from chronic pain. Kanan in partnership with Veterans in Pain recently performed his first pro bono procedure on a veteran named Ryan, who has severe hip pain. Stem cell injections into Ryans hip, which are not covered by insurance, normally would have cost $6,500. Ryan got them for free.

I think veterans do a lot for our country and there are very few doctors that are performing medical procedures like this, Kanan told The Tullahoma News. We were very glad to be able to do this for him.

Kanan says his Tennessee clinic performs stem cell therapy for veterans twice a month and has had good results so far. One patient was able to avoid a knee replacement and reported consistent improvement one year after the procedure. Patients can expect to experience 10 percent improvement every month for 10 months.

Veterans in Pain is a non-profit that connects military veterans with civilian physicians who provide free regenerative medicine treatments for chronic pain. VIP has provided $250,000 worth of services since 2019.

VIP founder and president Micaela Bensko is herself a stem cell therapy recipient. She spent years in a wheelchair after an accident in her driveway left her with severe spine damage that led to arachnoiditis, a chronic inflammation of spinal nerves. A friend suggested stem cell therapy, which inspired Bensko to establish VIP as a resource for veterans.

Veterans in Pain connects each veteran with a volunteer physician in their area. If one cannot be located, the cost of transportation and accommodations are covered for treatments, as they were for Ryan. Veterans associated with VIP visit schools, organizations and corporations sharing their story of recovery. Most of VIPs funding is provided by small individual donations, grants and grassroots fundraising.

According to the National Institutes of Health, nearly two-thirds of veterans report having chronic pain, with about 9% having severe pain. Chronic pain among veterans is closely associated with mental health conditions such as depression, anxiety, poor sleep and substance abuse disorders. Many veterans suffer from more than one condition.

Because of red tape and a shortage of pain management specialists at the VA, many veterans suffering from chronic pain are left devoid of proper diagnosis and treatment, causing many to self-medicate or search for answers on their own.Chronic pain can lead to substance abuse, a common and growing trend among veterans. A 2017 study found that 30% of military suicides were preceded by alcohol or drug abuse.

The dire plight of military veterans suffering from chronic pain is yet another compelling reason for the FDA to loosen its regulation of stem cell therapy. Our heroes are counting on it.

A. Rahman Ford, PhD, is a lawyer and research professional. He is a graduate of Rutgers University and the Howard University School of Law, where he served as Editor-in-Chief of the Howard Law Journal. Rahman lives with chronic inflammation in his digestive tract and is unable to eat solid food. He has received stem cell treatmentin China.

See the original post here:
Non-Profit Offers Free Stem Cell Therapy to Veterans - Pain News Network

Read More...

Morusin Ameliorates IL-1-Induced Chondrocyte Inflammation and Os | DDDT – Dove Medical Press

Friday, March 27th, 2020

Yewei Jia,1,* Wei He,1,* Hanxiao Zhang,2 Lei He,1 Yanben Wang,1 Tan Zhang,1 Jiaxuan Peng,3 Peng Sun,2 Yu Qian1

1Department of Orthopaedics, Shaoxing Hospital, Zhejiang University School of Medicine, Shaoxing, Zhejiang 312000, Peoples Republic of China; 2The Second Affiliated Hospital and Yuying Childrens Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, Peoples Republic of China; 3Guangxi Key Laboratory of Regenerative Medicine, Guangxi Medical University, Guangxi 530021, Peoples Republic of China

*These authors contributed equally to this work

Correspondence: Yu QianDepartment of Orthopaedics, Shaoxing Hospital, Zhejiang University School of Medicine, Shaoxing, Zhejiang 312000, Peoples Republic of ChinaTel +86 13905754033Email doctor120@hotmail.com

Purpose: Osteoarthritis (OA) is one of the most common degenerative joint diseases in the world, characterized primarily by the progressive degradation of articular cartilage. Accumulating evidence has shown that Morusin, a flavonoid derived from the root bark of Morus alba (mulberry) plants, exerts unique protective properties in several diseases. However, its effects on OA, specifically, have not yet been characterized.Methods: In this study, we evaluated the anti-inflammatory effect of Morusin on mouse chondrocytes and its underlying mechanism in vitro. In addition, the protective effect of Morusin on destabilization of the medial meniscus (DMM) model was also explored in vivo.Results: In vitro, IL-1-induced activation of inflammatory factors (TNF-, IL-6, INOS and COX2) was dramatically suppressed by Morusin. Further, Morusin treatment inhibited the expression of ADAMTS5 and metalloproteinase (MMPs), both of which regulate extracellular matrix degradation. Morusin also decreased IL-1-induced p65 phosphorylation and IB degradation. In vivo, degradation of the articular cartilage following surgical DMM, which mimicked OA pathology, was abrogated following treatment with Morusin, thus demonstrating a protective effect in the DMM model.Conclusion: Herein, we demonstrate that Morusin reduces the OA inflammatory response in vitro and protects against articular cartilage degradation in vivo potentially via regulation of the NF-B pathway. Hence, Morusin may prove to be an effective candidate for novel OA therapeutic strategies.

Keywords: osteoarthritis, chondrocytes, Morusin, IL-1, NF-B pathway

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Link:
Morusin Ameliorates IL-1-Induced Chondrocyte Inflammation and Os | DDDT - Dove Medical Press

Read More...

Another Unintended Consequence of COVID-19: Cyberbullying Could Increase – Newswise

Friday, March 27th, 2020

Newswise When smartphones and social media became ubiquitous for students, cyberbullying rates went up. This makes sense, of course, because there was now an almost limitless number of potential targets and aggressors, said Sameer Hinduja, Ph.D., a professor in the School of Criminology and Criminal Justice within FAUs College for Design and Social Inquiry, and co-director of the Cyberbullying Research Center. Well, during this unprecedented time when theyre all stuck at home, those same students will be using apps even more than they already do with them being forced to use online platforms for learning, regardless of their level of comfort or proficiency. Teachers are delivering education not just in learning management systems like Canvas, Blackboard, and Moodle, but even on Roblox, Twitch, and YouTube, among others.

In the midst of major crises where everyone is already on edge, Hinduja says hostility toward others tends to escalate along with self-preserving and self-defensive behaviors. This may manifest even more so between students in their online interactions their posts, comments, pictures and videos. Some of it will be mild, and some of it will be severe. Some of it will be what students are used to and will not bother them, but some of it will be brand new and a jarring, wounding experience. This may be especially true for those who are not used to learning and interacting in online-only spaces (and may also disproportionately affect more vulnerable populations of youth).

Hinduja cautions that many cyberbullying targets will hesitate to get help from their parents. When it happens, they may suffer silently since there will not be any visual cues for educators to see or investigate because the student is not physically at school. In addition, with everyone now receiving instruction online, students cannot readily stop by the guidance counselors office, chat with a teacher after class, or let their coach know about what is troubling them and affecting their ability to play sports (since youth sports also are shut down). Those opportunities for meaningful, connective conversations and check-ins largely will not happen organically.

Its also very possible that xenophobic/racist cyberbullying may go up. Some continue to call COVID-19 a foreign virus and parents have complained that their children are being accused as carriers just because they are Asian, said Hinduja. Im Asian and have dealt with my share of bullying based on race/ethnicity, and so I am particularly sensitive to this issue and simply do not want to see it spiral out of control.

Hinduja provides a number of suggestions for educators:

Students also are going to struggle with feelings of isolation because they are not able to go to school and connect and interact with their peers in person, said Hinduja.

He also suggests that parents need to be creative to make sure that their children do not suffer from extremes of social isolation:

With intentionality, graciousness, and good will, we dont have to just survive through this crisis. We can actually thrive, and our relationships with the youth we care for can be better off than they were before all of this even began, asserts Hinduja.

Additional information and tips can be found at the Cyberbullying Research Center.

- FAU -

About Florida Atlantic University: Florida Atlantic University, established in 1961, officially opened its doors in 1964 as the fifth public university in Florida. Today, the University, with an annual economic impact of $6.3 billion, serves more than 30,000 undergraduate and graduate students at sites throughout its six-county service region in southeast Florida. FAUs world-class teaching and research faculty serves students through 10 colleges: the Dorothy F. Schmidt College of Arts and Letters, the College of Business, the College for Design and Social Inquiry, the College of Education, the College of Engineering and Computer Science, the Graduate College, the Harriet L. Wilkes Honors College, the Charles E. Schmidt College of Medicine, the Christine E. Lynn College of Nursing and the Charles E. Schmidt College of Science. FAU is ranked as a High Research Activity institution by the Carnegie Foundation for the Advancement of Teaching. The University is placing special focus on the rapid development of critical areas that form the basis of its strategic plan: Healthy aging, biotech, coastal and marine issues, neuroscience, regenerative medicine, informatics, lifespan and the environment. These areas provide opportunities for faculty and students to build upon FAUs existing strengths in research and scholarship. For more information, visit fau.edu.

Read more here:
Another Unintended Consequence of COVID-19: Cyberbullying Could Increase - Newswise

Read More...

Vitro Biopharma First Quarter ended January 31, 2020 Financial Results of Operations – Benzinga

Friday, March 27th, 2020

GOLDEN, CO / ACCESSWIRE / March 26, 2020 / Vitro Diagnostics, Inc. (OTC:VODG), dba Vitro Biopharma, announced its 1st quarter ended January 31st, 2020 financial results of operations.

Vitro Diagnostics Inc. ("Vitro Biopharma") is pleased to announce a record 1st comparative quarter in Total Revenues. Vitro Biopharma recorded 1st quarter revenues of $225,921 vs $192,895 an increase of 17% over the same comparative quarter last year. In addition, Stem Cell treatments accounted for 74% of the revenues up from 71% of the revenues in the prior comparative quarter last year. Current quarter stem cell revenues were $167,750 for the 1st quarter ended January 31, 2020 vs $137,123 for the first quarter ended January 31, 2019.

The company's gross profit margins improved to 75% up from 73% in the comparative prior year's quarter. Gross margin improvement is in line with the strategic direction of the company to expand the market of its flagship product AlloRx Stem Cells. The company's clean-room lab expansion last year and expanded Stem Cell manufacturing using its patent-pending cell line, has increased efficiencies and lowered production costs.

Overall operating expenses increased in the quarter to $193,385 from $147,398 in the prior year's comparative quarter. The increase in expenses reflects additional investment as the Company expands its capability to service its strategic direction of offshore Stem Cell treatments while also expanding into US markets. The company expended additional resources on external consultants supporting our regulatory status in maintaining ISO9001 & ISO13485 certifications, expanding our efforts to approach US markets through FDA filings and advancement of existing patent filings.

The company's first quarter is its most seasonal quarter as the period between Thanksgiving and the New Year is slow for all the company's revenue lines of Nutra Vivo/STEMulize, AlloRx Stem Cells, private labeled InfiniVive-MD Stem Cell Serum and our core research products.

During the quarter the company achieved and pursed the following company objectives

During the quarter the company commenced a Series A Convertible Preferred Stock offering to accredited investors under the SEC Regulation D exemption. The preferred Stock is priced at $25 per share which is convertible at $0.25 cents per share for a total of 100 shares. The minimum investment is $50,000 per unit. The company sold $450,000 of the Series A Convertible Preferred Stock during the quarter. The company has additional interest in the offering and subsequent to the quarter has sold an additional $50,000 unit for a total to date of $500,000. The company has additional interested parties for approximately $200,000. The offering is for a total of $1,000,000.

Our partnership with DVC. Stem in the Cayman Islands continued to advance through treatment of new & previous patients. This IRB-approved protocol targets patients with inflammatory conditions including multiple sclerosis, systemic inflammation and new indications including Chrohn's disease, Alzheimer's disease and COPD. To date we have treated 60 patients including repeat treatments. There have been no serious adverse events and we continue to gain evidence of efficacy. One of the initial MS patients has now received a second transplant of our AlloRx Stem Cells and he has reported significant therapeutic benefits of both the initial and subsequent therapy. He had received an earlier transplant of adipose-derived MSCs that was effective, but the improvement lasted 3 months while AlloRx Stem Cell therapy lasted 18 months. We had predicted such a clinical outcome based on significantly higher potency of umbilical cord MSCS compared to those derived from adipose tissue or bone marrow. The Chrohn's disease patient showed significant improvement as did both the AD & COPD patients.

The strategic development of our stem cell therapies involves pursuit of both offshore and domestic markets. The partnership with DVC Stem, our IRB-approved trial in the Bahamas together with other strategic opportunities represent offshore operations & prospects. During Q1 2020, we initiated expansion into US therapeutic markets through development of an Investigational New Drug (IND) application for submission to FDA. Once approved, an IND allows the conduct of clinical trials for specific medical conditions in the US.

Given the current COVID-19 pandemic, our initial IND application is for use of AlloRx Stem Cells in treatment of Coronavirus infections. This is supported by clinical studies showing that 17 critically ill patients responded favorably to IV infusion of umbilical cord-derived MSCs. All patients were receiving assisted ventilation but 3 days following stem cell therapy, were removed from ventilators and subsequently discharged from the hospital. We are pursuing discussions with FDA to establish the appropriate regulatory pathway and expedited review options given the current emergency circumstances. (See Subsequent Events, below, for additional discussion of our COVID-19 response.) Once our initial IND is in place, we have plans for additional INDs for stem cell therapy of musculoskeletal conditions and Alzheimer's disease.

We have received an initial order of AlloRx Stem Cells for testing purposes by PR Medica located in Cabo San Lucas. Given successful test results, we anticipate subsequent new revenue generation from this customer.

Vitro Biopharma's cosmetic topical stem cell serum is being distributed by InfiniVive MD into cosmetic clinics that are providing the topical treatment as a beautification product. To date the company's product is being offered in 10 cosmetic clinics.

Our partner, Dr Jack Zamora, MD was a keynote speaker at a master session at the American Academy of Cosmetic Surgery annual meeting in late February. The topic of his presentation was "Topical Stem Cells, Exosomes and Conditioned Media Serums in Aesthetics." This was the official launch of the InfiniVive-MD platform including: Dailey Serum, Stem Cell Serum 2.0 & Exosomes within the product line. Vitro Biopharma will manufacture & private label these new products for distribution in the US. We anticipate InfiniVive MD growth, development and revenues to mirror the development of Apyx subdermal plasma skin tightening as a cosmetic treatment and technique that has gone global.

http://www.jackzamoramd.com http://www.infinivivemd.com

Our core research product sales continued to expand in Q1 2020. Our facility expansion continued with addition of manufacturing capacity and development of plans to add operational facility to increase outputs further by 100% or more. We were also in discussions with the USPTO regarding our pending patents for our novel stem cell therapy and stem cell activation technology. We continue to work closely with our examiner and have established communication channels to facilitate awards of these patents.

The COVD-19 pandemic is a significant obstacle for all business. However, Vitro Biopharma is uniquely positioned since we have a potential effective therapy. This is based on 3 independent reports showing efficacy of stem cell therapy in 17 COVID-19 patients. All were treated with IV umbilical cord MSCs comparable to AlloRx Stem Cells and all 17 required respiratory assistance but within 3-4 days of treatment, were able to breath without ventilators and were discharged within 14 days. https://www.scmp.com/news/china/society/article/3053080/coronavirus-critically-ill-chinese-patient-saved-stem-cell On the contrary, untreated patients on ventilators have death rates of 50% or more. We have received a formal request to supply AlloRx Stem Cells for compassionate use from a major university medical center and several other potential clinical partners have also expressed interest in using our cells to treat COVID-19 patients. We are presently working with the FDA to gain authority to begin clinical testing in the US. We are currently assessing the overall financial impact of the COVID-19 pandemic on our business, but this depends on overall control of the pandemic. There have been no staff layoffs and our workers are considered essential since we conduct essential research to the COVID-19 response.

Dr. Jim Musick, CEO of Vitro Biopharma, said, "We are very pleased with the increased revenue growth during our first quarter 2020 compared to the prior year However all our resources are currently focused on the emergency response to the COVID-19 pandemic and increasing our inventory of AlloRx to satisfy anticipated emergency demand to treat critically ill COVID-19 patients." The Company is working to get expedited clinical trial approvals to sell our AlloRx Stem Cells to hospitals coping with the pandemic. Vitro is pleased to have recently been recognized by Bioinformant as "a Company Tracking the Coronavirus". https://bioinformant.com/product/coronavirus-covid-19-report/ We anticipate clinical progress in the effectiveness of our stem cell therapies while expecting to see a reduction in our offshore and cosmetic revenues for the next quarter or two. The company is in a good cash position to weather this storm and simultaneously advance its AlloRx stem cell therapies into clinical trials.

In summary, Vitro Biopharma is advancing as a key player in regenerative medicine with 10- years' experience in the development and commercialization of stem cell products for research, recognized by a Best in Practice Technology Innovation Leadership award for Stem Cell Tools and Technology and a growing track record of successful translation to therapy. We are leveraging our proprietary technology platform to the establishment of international Stem Cell Centers of Excellence and regulatory approvals in the US and worldwide.

Sincerely yours,

James R. Musick, PhD.President, CEO & Chairman of the Boardwww.vitrobiopharma.com

Forward-Looking Statements

Statements herein regarding financial performance have not yet been reported to the SEC nor reviewed by the Company's auditors. Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain "forward-looking statements". Such forward looking statements are identified by words such as "intends," "anticipates," "believes," "expects" and "hopes" and include, without limitation, statements regarding the Company's plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company's products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company's filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT:

Dr. James MusickChief Executive OfficerVitro BioPharma(303) 999-2130 Ext. 3E-mail: jim@vitrobiopharma.comwww.vitrobiopharma.com

The company provides its financial information for investor purposes only, the results published are not audited or necessarily SEC or GAAP compliant

The company provides its financial information for investor purposes only, the results published are not audited or necessarily SEC or GAAP compliant

The company provides its financial information for investor purposes only, the results published are not audited or necessarily SEC or GAAP compliant.

The company provides its financial information for investor purposes only, the results published are not audited or necessarily SEC or GAAP compliant.

SOURCE: Vitro Diagnostics, Inc.

View source version on accesswire.com: https://www.accesswire.com/582759/Vitro-Biopharma-First-Quarter-ended-January-31-2020-Financial-Results-of-Operations

Read the original post:
Vitro Biopharma First Quarter ended January 31, 2020 Financial Results of Operations - Benzinga

Read More...

Page 24«..1020..23242526..3040..»


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick